Development of human bispecific antibodies against CD20/CD55 or CD20/CD59 for the treatment of Burkitt lymphoma

被引：0
|
作者：
Macor, P. [1 ]
Secco, E. [1 ]
Mezzaroba, N. [1 ]
De Maso, L. [1 ]
Durigutto, P. [1 ]
Gaiotto, T. [1 ]
Garrovo, C. [2 ]
Biffi, F. [2 ]
Zorzet, S. [1 ]
Sblattero, D. [3 ]
Tedesco, F. [1 ]
机构：
[1] Univ Trieste, Dept Life Sci, Trieste, Italy
[2] CBM, Opt Imaging Lab, Trieste, Italy
[3] Univ Piemonte Orientale, Dept Med Sci, Novara, Italy
来源：
MOLECULAR IMMUNOLOGY | 2010年 / 47卷 / 13期
关键词：
D O I：
10.1016/j.molimm.2010.05.264
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
82
引用
收藏
页码：2287 / 2287
页数：1
相关论文
共 50 条
  • [1] Characterization of a human bispecific antibody against CD20/CD55 for the treatment of burkitt lymphoma
    Macor, Paolo
    Mezzaroba, Nelly
    De Maso, Luca
    Garrovo, Chiara
    Biffi, Stefania
    Sblattero, Daniele
    Marzari, Roberto
    Tedesco, Francesco
    IMMUNOBIOLOGY, 2012, 217 (11) : 1149 - 1150
  • [2] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [3] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma
    Justyna Dzietczenia
    Tomasz Wróbel
    Grzegorz Mazur
    Rafał Poręba
    Bożena Jaźwiec
    Kazimierz Kuliczkowski
    Medical Oncology, 2010, 27 : 743 - 746
  • [4] Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin's lymphoma
    Dzietczenia, Justyna
    Wrobel, Tomasz
    Mazur, Grzegorz
    Poreba, Rafal
    Jazwiec, Bozena
    Kuliczkowski, Kazimierz
    MEDICAL ONCOLOGY, 2010, 27 (03) : 743 - 746
  • [5] The susceptibility of freshly isolated B-non Hodgkin lymphoma cells to Rituximab and complement is determined by CD20 levels and the CD55/CD59 inhibitors.
    Golay, J
    Lazzari, M
    Facchinetti, V
    Borleri, G
    Dastoli, G
    Barbui, T
    Introna, M
    Rambaldi, A
    BLOOD, 2000, 96 (11) : 338A - 338A
  • [6] The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
    Teeling, Jessica L.
    Mackus, Wendy J. M.
    Wiegman, Luus J. J. M.
    van den Brakel, Jeroen H. N.
    Beers, Stephen A.
    French, Ruth R.
    van Meerten, Tom
    Ebeling, Saskia
    Vink, Tom
    Slootstra, Jerry W.
    Parren, Paul W. H. I.
    Glennie, Martin J.
    van de Winkel, Jan G. J.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (01): : 362 - 371
  • [7] CD20
    Warzynski, MJ
    Graham, DM
    Axtell, RA
    Zakem, MH
    Rotman, RK
    APPLIED IMMUNOHISTOCHEMISTRY, 1996, 4 (03): : 218 - 218
  • [8] CD20
    Macardle, PJ
    Nicholson, IC
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2002, 16 (02): : 136 - 138
  • [9] Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
    Huang, Hongpeng
    Wei, Xuetao
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2025, 5 (04): : 209 - 216
  • [10] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Golay, J
    Lazzari, M
    Facchinetti, V
    Bernasconi, S
    Borleri, G
    Barbui, T
    Rambaldi, A
    Introna, M
    BLOOD, 2001, 98 (12) : 3383 - 3389
12345